期刊文献+

肢端肥大症合并心脏损害1例并文献复习

下载PDF
导出
摘要 肢端肥大症是垂体生长激素腺瘤在成年期的临床表现。该病起病隐匿,进展缓慢,初次就诊原因可以是其继发的其他系统器官病变,如高血压、糖尿病、睡眠呼吸暂停综合征等,接诊医生有意识关注患者体征及必要时完善垂体相关检查,才能避免漏诊及更全面评估患者病情。肢端肥大症目前的治疗方式是以手术治疗为主的综合治疗,其围术期治疗尤以心血管系统及呼吸系统为重。
出处 《现代医药卫生》 2016年第14期2270-2272,共3页 Journal of Modern Medicine & Health
  • 相关文献

参考文献16

  • 1Melmed S. Acromegaly[J]. N Engl J Med, 1990,322 (14) : 966-977.
  • 2Fazio S, Cittadini A, Biondi B, et al. Cardiovascular effects of short-term growth hormone hypersecretion[J]. J Clin Endocrinol Metab,2000,85 (1): 179-182.
  • 3Legrand V, Beckers A, Pham VT,et al. Dramatic improvement of severe dilated cardiomyopathy in an acromegalic patient after treatment with octreo- tide and trans-sphenoidal surgery I J]. Eur Heart J, 1994,15 (9) : 1286-1289.
  • 4Dutta P, Das S, Bhansali A, et al. Congestive heart failure in acromegaly : A review of 6 cases[J]. Indian J Endocrinol Metab, 2012,16 (6) :987-990.
  • 5傅勇,王景全.肢端肥大症性心脏病[J].吉林医学,1993,14(2):65-66. 被引量:1
  • 6杨萍.注射用醋酸奥曲肽微球[J].中国新药杂志,2005,14(10):1230-1231. 被引量:4
  • 7Cozzi R, Attanasio R. Octreotide long-acting repeatable for acromegaly[J]. Expert Rev Clin Pharmacol, 2012,5 (2) : 125-143.
  • 8Maison P,Tropeano AI,Macquin-Mavier I,et al. Impact of somatostatin analogson the heart in acromegaly:a metaanalysis[J]. J Clin Endocrinol Metab, 2007,92(5) : 1743-1747.
  • 9Colao A, Marzullo P, Cuocolo A, et al. Reversal of acromegalic cardiomyo- pathy in young but not in middle-aged patients after 12 months of treat- ment with the depot long-acting somatostatin analogue octreotide[J]. Clin Endocrinol (Oxf) ,2003,58 (2) : 169-176.
  • 10Jayasena CN, Comninos AN, Clarke H, et al. The effects of long-term growth hormone and insulin-like gro~h factor-1 exposure on the develop- ment of cardiovascular,cerebrovascular and metabolic co-morbidities in treated patients with acromegaly[J]. Clin Endocrinol (Oxf), 2011,75 (2): 220-225.

二级参考文献13

  • 1毛志钢,王海军,何东升,徐伟光,冯雷.影响垂体生长激素腺瘤经蝶手术疗效的因素分析[J].中国微侵袭神经外科杂志,2006,11(4):151-153. 被引量:7
  • 2Melmed S, Casanueva FF, Cavagnini AF, et al. Guidelines for acromegaly management [J]. J Clin Endocrinol Metab,2002; 87(9):.4054-4058.
  • 3Bevan JS, Atkin SL, Atkinson AB. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I,and tumor size [J]. J Clin Endocrinol Metab, 2002; 87(10):4554-4563.
  • 4Trainer P, Drake WM, Katznelson L, et al. Treatment of acromegaly with growth hormone receptor antagonist pegvisomant [J]. N Engl J Med, 2000; 342(16): 1171-1177.
  • 5Ben-shlomo A, Melmed S. Clinical review 154: the role of pharmacotherapy in perioperative management of patients with acromegaly [J]. J Clin Endocrinol Metab, 2003; 88(3):963-968.
  • 6Ghosh AK. Factors involved in the regulation of type I collagen gene expression: implication in fibrosis [J]. Exp Biol Med (Maywood), 2002; 227(5): 301-314.
  • 7Naganuma H, Satoh E, Nukui H. Technical consideration of transsphenoidal removal of fibrous pituitary adenomas and evaluation of collagen content and subtype in the adenomas[J]. Neurol Med Chir (Tokyo), 2002; 42(5): 202-213.
  • 8Schuppan D, Koda M, Bauer M, et al. Fibrosis of liver, pancreas and intestine: common mechanisms and clear targets[J]? Acta Gastroenterol Belg, 2000; 63(4): 366-370.
  • 9Gore-Hyer E, Shegogue D, Markiewicz M, et al. TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells [J]. Am J Physiol Renal Physiol, 2002;283(4): 707-716.
  • 10Crean JK, Finlay D, Murphy M, et al. The role of p42/44MAPK and protein kinase B in connective tissue growthfactor induced extracellular matrix protein production, cell migration, and actin cytoskeletal rearrangement in human messagial cells [J]. J Biol Chern, 2002; 277(46): 44187-44194.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部